Condition: Cancer · Pulmonary Embolism · Thrombosis · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging as a tool. The investigators to measure TGA in cancer patients included prospectively, having recently developed a CAT and to evaluate the association between the measurement and the risk of hemorrhagic complication under anticoagulant during the first 6 month of treatment.
This description comes directly from the study's public registry record.
Géraldine POENOU, MD PHD · (0)477828919 · geraldine.poenou@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| Chu Clermont-Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| CHU de Grenoble | Grenoble, France | Not Yet Recruiting |
| HCL | Lyon, France | Not Yet Recruiting |
| Chu St-Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06386107